Leerink analyst David Larsen continues to be positive on CVS' (CVS) long-term fundamentals. The analyst notes that the company is having a successful 2017 selling season, with a retention rate higher than what it was last year, and says its Q3 should benefit from a number of break-even generics. Further, Larsen says the company is being more aggressive than Express Scripts (ESRX) with regards to formulary management, and believes that if CVS provides a 5-year outlook in December, shares will likely rally. Larsen reiterates an Outperform rating and $110 rating on CVS' shares.